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Abstract 
Background: An Informatics Consult has been proposed in which clinicians request novel evidence from large scale 
health data resources, tailored to the treatment of a specific patient. However, the availability of such consultations is 
lacking. We seek to provide an Informatics Consult for a situation where a treatment indication and contraindication 
coexist in the same patient, i.e., anti-coagulation use for stroke prevention in a patient with both atrial fibrillation (AF) 
and liver cirrhosis.
Methods: We examined four sources of evidence for the effect of warfarin on stroke risk or all-cause mortality from: 
(1) randomised controlled trials (RCTs), (2) meta-analysis of prior observational studies, (3) trial emulation (using popu-
lation electronic health records (N = 3,854,710) and (4) genetic evidence (Mendelian randomisation). We developed 
prototype forms to request an Informatics Consult and return of results in electronic health record systems.
Results: We found 0 RCT reports and 0 trials recruiting for patients with AF and cirrhosis. We found broad concord-
ance across the three new sources of evidence we generated. Meta-analysis of prior observational studies showed 
that warfarin use was associated with lower stroke risk (hazard ratio [HR] = 0.71, CI 0.39–1.29). In a target trial emula-
tion, warfarin was associated with lower all-cause mortality (HR = 0.61, CI 0.49–0.76) and ischaemic stroke (HR = 0.27, 
CI 0.08–0.91). Mendelian randomisation served as a drug target validation where we found that lower levels of vitamin 
K1 (warfarin is a vitamin K1 antagonist) are associated with lower stroke risk. A pilot survey with an independent sam-
ple of 34 clinicians revealed that 85% of clinicians found information on prognosis useful and that 79% thought that 
they should have access to the Informatics Consult as a service within their healthcare systems. We identified candi-
date steps for automation to scale evidence generation and to accelerate the return of results.
Conclusion: We performed a proof-of-concept Informatics Consult for evidence generation, which may inform 
treatment decisions in situations where there is dearth of randomised trials. Patients are surprised to know that their 
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Background
Evidence informing treatment decisions traditionally 
takes years to generate and leaves many clinical uncer-
tainties unaddressed [1]. Especially in patients with two 
or more conditions (multimorbidity), it has been hard 
to generate evidence tailored to ‘patients like me’ and 
embed this evidence in clinical decision making using 
electronic health records. There are thousands of clini-
cal practice recommendations, but only a small propor-
tion (15–20%) of these recommendations are supported 
by level A (trial) evidence [1–6]. A systematic review of 
trial registration records found that 79% of randomised 
controlled trials (RCTs) excluded patients with con-
comitant chronic conditions [6]. The United States 
Food and Drug Administration, Medicines Healthcare 
Regulatory Authority and European Medicines Agency 
are increasingly recognising the role of real-world evi-
dence [7] but guidance thus far has not considered its 
near real-time generation.
The Informatics Consult concept has been proposed 
[8–11] to produce on-demand evidence in which clini-
cians request novel evidence based on the care of prior 
patients to inform the treatment of a specific patient, 
with return of results in decision-relevant clinical time-
scales. For example, a hepatologist seeing a patient with 
cirrhosis in the clinic learns that they have developed 
atrial fibrillation. What evidence is, or could rapidly be, 
available to inform a decision on anti-coagulation for 
stroke prevention? This is an example of a treatment 
indication and a treatment contra-indication coexist-
ing in the same patient. Initial experience of the Infor-
matics Consult from Stanford University, has focussed 
on questions of prognosis (rather than treatment deci-
sions) and highlighted analytical and scaling challenges 
in returning results [11]. However, demonstrators of 
the Informatics Consult for treatment decisions are 
lacking.
Our objective was to demonstrate proof of concept 
of the Informatics Consult using the atrial fibrillation-
cirrhosis-warfarin example. Specifically, we sought to 
(1) develop prototype electronic health record forms 
for requesting an Informatics Consult and return of 
results, (2) generate four sources of evidence for an 
Informatics Consult (evaluate available RCT evidence, 
meta-analyse prior observational studies, emulate a tar-
get trial using electronic health records, and Mendelian 
randomisation [12, 13]), (3) for each form of evidence, 
to identify steps necessary for automation to accelerate 
evidence generation and return of results to clinicians, 
and scale across multiple exemplars (Additional file 1-
1) and (4) explore clinician acceptability of the Infor-
matics Consult.
Methods
Developing prototype electronic health record (EHR) 
request form and report form
An Informatics Consult is triggered by a request made 
by a clinician from the electronic health records (EHR) 
for multiple novel sources of evidence. We developed 
prototypes for the request form and the report form in 
consultation with the Chief Clinical Research Informat-
ics Officer and clinicians (cardiologists, hepatologists and 
clinical pharmacologists). We illustrate possible forms 
based on an EHR platform, but similar design principles 
are relevant in EHRs from other vendors, and in other 
settings, including primary care.
Retrieving information on currently recruiting trials
We searched for previously reported and currently 
recruiting trials on anticoagulants in patients with atrial 
fibrillation, with stroke or mortality in the primary out-
come using the ClinicalTrials.gov registry. We then used 
the 8-digit National Clinical Trial numbers to retrieve 
detailed information on inclusion and exclusion criteria 
for each trial to identify if any trials included patients 
with both atrial fibrillation and cirrhosis.
Meta‑analysis of prior observational studies
Study identification We searched PubMed for peer-
reviewed articles using the keywords “antithrombotic”, 
“anticoagulant”, “warfarin”, “cirrhosis” and “atrial fibril-
lation”. We considered eligible studies as those reporting 
the effects of anticoagulation therapy in patients with 
both liver cirrhosis and atrial fibrillation. We excluded 
reviews, single case reports, editorials and small case 
series (< 10 cases). Data extraction We extracted the 
following variables: author, setting, eligibility criteria, 
number of patients with atrial fibrillation and cirrhosis, 
number of patients in treated and untreated groups and 
summary measures. Analyses were performed following 
PRISMA guidelines. Outcomes of interest were mortality 
and ischaemic stroke. Statistical analysis A meta-analysis 
of associations was performed by pooling hazard ratios 
(HRs) or odds ratios (ORs) depending on data availability 
from observational studies using DerSimonian and Laird 
clinicians are currently not able to learn in clinic from data on ‘patients like me’. We identify the key challenges in offer-
ing such an Informatics Consult as a service.
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random-effects models. We also performed leave-one-
out sensitivity analyses.
Target trial emulation
We used population-based EHRs to perform a target trial 
emulation, which is the application of design principles 
from RCTs to inform analyses on observational data [14, 
15]. We obtained informational governance approval 
from the Medicines Healthcare Regulatory Author-
ity (UK) Independent Scientific Advisory Commit-
tee (20_078R) to analyse the Clinical Practice Research 
Datalink (CPRD) linked to secondary care Hospital Epi-
sode Statistics and the Office for National Statistic death 
registration. The study population was 3,854,710 adults 
aged ≥ 30  years. Phenotype definitions for atrial fibril-
lation, cirrhosis and other conditions included as base-
line covariates as well as definitions for prescriptions are 
available at https:// calib erres earch. org/ portal and have 
previously been validated [16, 17]. Phenotypes for pri-
mary care records were generated using Read clinical 
terminology (version 2). Phenotypes for secondary care 
records were generated using ICD-10 terms.
We developed a target trial protocol where eligibil-
ity criteria, treatment assignment, treatment strategy, 
follow-up period, causal contrast and statistical analy-
ses were specified (Additional file 1-2). Each component 
of the trial protocol is matched as closely as possible to 
the design of a randomised trial with minor modifica-
tions to accommodate the use of observational data. We 
employed the intention-to-treat effect as a causal con-
trast, which was warfarin initiation versus no initiation at 
baseline. To emulate a target trial, we ensured that indi-
viduals are classified as warfarin initiators versus non-
initiators at baseline (i.e., using baseline information to 
assign baseline treatment status). The baseline is defined 
as the latest date by which a patient has both cirrhosis 
and atrial fibrillation given that all eligibility criteria are 
met. As we were interested in assessing the effects of 
warfarin use on stroke, we have also excluded prevalent 
cases of ischaemic stroke. Individuals were followed until 
the development of an outcome of interest, which were 
all-cause mortality and incident ischaemic stroke. Pro-
pensity score matching (PSM) analyses were performed 
by matching the warfarin initiator and non-initiator 
groups. PSM was performed using the nearest-neighbour 
matching method (a 1:3 match was performed where 
possible) with a calliper width of 0.2 of the standard 
deviation of the logit of the propensity score. The PSM 
cohort was subjected to analyses of all-cause mortality 
and incident stroke using the Kaplan–Meier and logrank 
test method and the Cox proportional hazard regression 
model. As patients and clinicians would be interested in 
understanding risk in specific demographic categories, 
we performed subgroup analyses for all-cause mortal-
ity in patients aged ≤ 65, aged > 65, men, women and in 
patients with normal international normalise ratio (INR) 
measurements.
Genetic evidence: two‑sample Mendelian randomisation 
(MR)
As an example of drug target validation in the general 
population, we performed MR to investigate the causal 
relationship between warfarin use and stroke risk. Vita-
min K1 (phylloquinone) is a central component in the 
production of blood coagulation factors. Warfarin (a vita-
min K antagonist) inhibits the activity of vitamin K epox-
ide reductase to interfere with the recycling of vitamin K 
and to reduce blood clotting. We considered four single 
nucleotide polymorphisms (SNPs) that predict circulat-
ing phylloquinone (vitamin K1) selected from a genome-
wide meta-analysis study on Europeans [18]. Four SNPs, 
all on separate chromosomes, were selected as they had 
the strongest association with circulating phylloquinone: 
rs2108622 (chromosome 19), rs2192574 (chromosome 2), 
rs4645543 (chromosome 8) and rs6862071 (chromosome 
5). We retrieved genome wide association study (GWAS) 
summarised data for stroke outcomes from the MEGAS-
TROKE study [19]. MR was performed using the “Men-
delianRandomisation” package in R [20]. We explored 
four methods for MR; inverse-variance weighted (IVW), 
MR-Egger, simple median and weighted median.
Potential for automating the informatics consult
We tasked a review panel with expertise in health infor-
matics, epidemiology, evidence synthesis and computer 
science (drawn from co-authors) with two questions: (1) 
What are the most time-consuming tasks for each of the 
4 streams of evidence identification and generation? (2) 
What automation opportunities might be important for 
acceleration and scaling.
Clinician acceptability of the informatics consult
After the initial development of the Consult, to gain 
insights into the acceptability and feasibility of the Infor-
matics Consult, we conducted a pilot survey with an 
independent sample of 34 clinicians who had not taken 
part in the research.
Results
Prototype EHR request form
Clinicians wanted the request form (Fig.  1) to include 
a succinct free text statement of the clinical question, 
auto propagation of the diagnosis combination from the 
patient’s EHR, and suggested structured treatment, effi-
cacy and safety outcomes, based on inputs from the sur-
vey. Some clinicians wanted to further specify eligibility 
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criteria for target trial emulation. Interestingly clinicians 
wanted not only evidence directly related to treatment 
effectiveness, but also requested national prevalence esti-
mates of cirrhosis and atrial fibrillation, prognosis (1-year 
mortality), and current treatment variation (proportion 
of warfarin initiators).
Prototype EHR report
We provide an overall summary report based on new 
evidence on warfarin use (lower all-cause mortality and 
lower stroke risk) in patients with atrial fibrillation and 
cirrhosis (Fig. 2). Through the Consult report, clinicians 
will have the opportunity to queue patients for RCTs 
where relevant. We summarise evidence on prevalence, 
1-year background mortality risk, meta-analysis of obser-
vational studies, target trial emulation results and genetic 
evidence. The detailed results included in the report for 
each form of evidence were provided below.
Reported and currently recruiting randomised trials
We did not identify any previous reported RCTs on anti-
coagulants relevant to patients with cirrhosis. We identi-
fied four currently recruiting anticoagulant trials. All four 
trials reported exclusion criteria related to liver cirrhosis 
such as contraindication to anticoagulation, i.e., hepatic 
impairment and elevated liver function tests (Fig. 3).
Meta‑analysis of observational studies on warfarin use 
and ischaemic stroke
We identified 142 articles from PubMed, of which only 
4 observational studies remained eligible on full-text 
review, and were included in the meta-analysis [21–24] 
(Fig.  4A). The pooled hazard ratio (HR) of warfarin use 
in patients with atrial fibrillation and cirrhosis on stroke 
was 0.71, 95% confidence interval [CI] (CI = 0.39–1.29), 
with high heterogeneity between studies  I2 = 73% 
(Fig. 4B). We also performed the leave-one-out sensitivity 
analysis with HRs ranging from 0.54 (CI = 0.30–1.00) to 
0.92 (CI = 0.55–1.54). Only 1 study reported warfarin use 
and all-cause mortality and found a lower mortality risk 
(HR = 0.65; = 0.55–0.76) [21].
Target trial emulation using population‑based EHRs
Per the target trial protocol (Additional file 1-2), a cohort 
encompassing 1022 individuals fulfilling all eligibility cri-
teria was created (initiators = 443; non-initiators = 579). 
We performed PSM on 22 baseline covariates and gen-
erated a matched cohort involving 235 initiators and 526 
non-initiators (Fig.  5A), baseline patient characteristics 
Fig. 1 Informatics Consult Electronic health record request form prototype
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Fig. 2 Informatics Consult Electronic health record report prototype
Clinical question:
Is oral anti-coagulation therapy safe and effective in reducing 
stroke risk in people with cirrhosis and atrial fibrillation?
Previously reported randomised trials on anticoagulants available for patients with cirrhosis = 0
Currently recruiting anti-coagulant trials with stroke as an outcome = 4
Currently recruiting trials available for patients with cirrhosis  = 0
Are there existing randomised controlled trials (RCTs) that 
provide sufficient evidence?
A
B National Clinical 
Trial number
Trial acronym Drug comparisons Inclusion Exclusion Primary outcome
Previously completed trials
NCT00262600 RE-LY Dabigatran vs warfarin Non-valvular atrial fibrillation Patients with cirrhosis excluded Stroke or systemic embolic event
NCT00403767 ROCKET AF Rivaroxaban vs warfarin Atrial fibrillation, history of a 
prior stroke
Patients with cirrhosis excluded Stroke or systemic embolic event
NCT00412984 ARISTOTLE Apixaban vs warfarin Atrial fibrillation Patients with cirrhosis excluded Stroke or systemic embolic event
NCT00781391 ENGAGE AF-TIMI Edoxaban vs warfarin Atrial fibrillation Patients with cirrhosis excluded Stroke or systemic embolic event
Currently recruiting trials
NCT03148457 ELAN Early treatment vs late treatment 
with rivaroxaban, dabigatran, 
apixaban or edoxaban
Persistent atrial fibrillation 
and ischaemic stroke
Patients with cirrhosis excluded Recurrent stroke, major bleeding, 
systemic embolic event
NCT03759938 OPTIMAS Early treatment vs standard 
treatment with rivaroxaban, 
dabigatran, apixaban or edoxaban
Atrial fibrillation and acute 
stroke
Patients with cirrhosis excluded Stroke, intracranial haemorrhage and 
systemic embolic event
NCT02618577 NOAH Edoxaban vs aspirin Atrial High Rate Episodes Patients with cirrhosis excluded Stroke, systemic embolic event, 
cardiovascular death
NCT01938248 ARTESiA Apixaban vs aspirin Sub-clinical atrial fibrillation Patients with cirrhosis excluded Stroke or systemic embolic event
Fig. 3 Trial evidence and currently recruiting trials of anticoagulation in patients with atrial fibrillation and cirrhosis to reduce stroke risk. A Clinical 
question and summary of trial evidence. B Previously completed and currently recruiting randomised trials evaluating anticoagulants and stroke 
outcomes have exclusion criteria related to cirrhosis
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before and after PSM are shown in Additional file  1-
3. We estimated an intention-to-treat HR for all-cause 
mortality of 0.61 (CI = 0.49–0.76; p < 0.0001) comparing 
warfarin initiators with non-initiators (Fig.  5B). War-
farin used was associated with lower risk of ischaemic 
stroke: HR = 0.27 (CI = 0.08–0.91, p = 0.034) (Fig.  5B). 
The 1022 eligible participants for the target trial were 
categorised into the five subgroups (aged ≤ 65, aged > 65, 
men, women and patients with normal INR), followed by 
PSM (Additional file 1-4; Additional file 1-5; Additional 
file 1-6; Additional file 1-7; Additional file 1-8; Additional 
file  1-9). Intention-to-treat HRs for all-cause mortality 
comparing warfarin initiators versus non-initiators were 
as follow: aged ≤ 65: HR = 0.62 (0.45–0.86, p = 0.0041); 
aged > 65: HR = 0.61 (0.46–0.83, p = 0.0015); men: 
HR = 0.64 (0.49–0.84, p = 0.0014); women: HR = 0.53 
(0.37–0.77, p = 0.00087) and normal INR of < 1.7: 
HR = 0.62 (0.50–0.78, p < 0.0001), where warfarin ther-
apy is associated with lower mortality risk (Additional 
file 1-4).
Genetic evidence
We found no GWAS summary data for vitamin K1 in 
patients with atrial fibrillation and cirrhosis, but we 
did find genetic evidence to indicate that warfarin use 
is associated with reduced stroke risk. For two-sample 
MR, we used four methods (inverse-variance weighted 
(IVW), MR-Egger, simple median and weighted median). 
The IVW analyses, which assumes no pleiotropy, 
revealed that higher genetically predicted levels of vita-
min K1 were associated with a higher risk of any stroke 
with an odds ratio (OR) of 1.06 (95% CI 1.00–1.11) per 
Ln-nmol/L increase in vitamin K1 (Fig.  6). However, 
these results were not replicated using methods (simple 
median, weighted median and MR-Egger) which allow for 
genetic pleiotropy. When considering stroke subtypes, 
we observed that higher genetically predicted levels of 
vitamin K1 were associated with a higher risk of large 
artery atherosclerotic stroke for 3 out of 4 MR methods: 
simple median (OR = 1.25 [1.03–1.51]); weighted median 
(OR = 1.25 [1.03–1.52]) and IVW (OR = 1.29 [1.11–1.50]) 
(Fig. 6).
Informatics consult report generation
Table  1 shows additional opportunities for pipelining 
each of the four streams of evidence identification and 
generation to return the Consult report. Computable 
EHR phenotypes and computable clinical trial protocols 
Fig. 4 New synthesis of prior observational evidence. Meta-analysis of the association between warfarin use and the risk of ischaemic stroke 
in observational studies including approaches for automation. A Characteristics of observational studies included in the meta-analysis. B Forest 
plot depicting the hazard ratios calculated with the DerSimonian and Laird random-effects models. HR = hazard ratio; CI = confidence interval; 
SE = standard error
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can be used to automate the process of trial identifica-
tion and trial recruitment [25, 26]. For meta-analyses of 
observational studies, approaches for semi-automated 
systematic reviews [27, 28], batch extraction of data from 
articles [29, 30] and mapping of SNOMED-CT terms to 
MeSH descriptors in PubMed [31] can be used in the 
pipelining process. The DExtER tool can be used for 
automatic extraction of EHR databases and automated 
Fig. 5 New observational evidence through target trial emulation (intention-to-treat analysis) where eligibility and treatment assignment were 
aligned with time zero of follow-up, as is done in randomised controlled trials. A CONSORT diagram showing the selection of eligible individuals for 
the target trial emulation of anticoagulation therapy in patients with atrial fibrillation and cirrhosis. B Kaplan–Meier plots of the propensity-matched 
cohort for all-cause mortality and ischaemic stroke. Flow diagram depicts analysis design. P values from logrank tests were indicated. Hazard ratios 
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Fig. 6 Genetic evidence. Two-sample Mendelian randomisation on circulating vitamin K1 levels and risk of stroke. *Indicate significant results
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cohort creation for the target trial emulation process 
[32]. Recent addition of an analytical module to DExtER 
enables cohort creation, statistical analyses and results 
visualisation within short time scales for matched cohort 
studies. Two-sample MR to generate genetic evidence 
can be automated using the MR-Base platform [33], 
which returns results within minutes.
Clinician survey on the acceptability and feasibility 
of the Informatics Consult
We surveyed an independent sample of 34 clinicians 
from eight specialties with results shown in (Additional 
file 1-10, Additional file 1-11). Results indicated that 79% 
of clinicians thought that they should have access to the 
Informatics Consult as a service within their healthcare 
systems (21% responded ‘maybe). Clinicians found each 
section of the report useful (or ‘maybe useful’) as follows: 
prognosis [85% useful (12% maybe useful)], a summary of 
evidence of efficacy and safety [79% useful (21% maybe 
useful)] and disease prevalence [68% useful (18% maybe 
useful)]. Only 18% of clinicians thought that they needed 
to have access to the details of the evidence in the clinic 
with one clinician stating: “Multi-disciplinary team meet-
ings might benefit from Informatics Consults, this is where 
difficult cases are discussed and there is time to review 
newly generated evidence”. When asked whether clini-
cians found detailed reports on the four sources of evi-
dence useful (or ‘maybe useful’), responses were as follow: 
randomised trials: 82% useful (15% maybe useful); meta-
analysis of prior observational evidence: 76% useful (18% 
maybe useful); target trial emulation: 62% useful (18% 
maybe useful) and genetic evidence: 26% useful (24% 
maybe useful). 74% of clinicians would discuss the Infor-
matics Consult report with their patients (26% answered 
maybe). Clinicians offered 15 further clinical questions 
where the Informatics Consult might be of value and 
made additional comments including: “Ultimately, we 
practise defensive medicine—would my decision stand up 
in court based on available data—the Informatics Con-
sult should help with that.” and “Regulators and guideline 
developers will require replication and quality assurance 
of evidence generated in clinical timescales”.
Discussion
We demonstrate that the Informatics Consult offers a 
novel paradigm to generate new clinical evidence. We 
found that in patients with atrial fibrillation and cirrho-
sis, initiation of warfarin was common, may be associ-
ated with lower all-cause mortality and may be effective 
in lowering stroke risk. Given the ubiquity of clinical 
uncertainty where there is little or no evidence, and that 
current modes of generating new evidence may never be 
initiated or, if initiated, take years to report, it is impera-
tive to accelerate learning from extant data.
Informatics consult versus traditional approaches 
for evidence generation and delivery
The Informatics Consult puts the treating clinician and 
the patient at the centre of evidence generation. Indeed, 
in seeking to address a range of questions from the clini-
cian and patient, the Informatics Consult, if automation 
is plausible, could enable the simultaneous delivery of 
evidence from different sources, rather than employing a 
one-study-one-design-at-a-time approach. The Consult 
is embedded within EHR system—making it a form of an 
electronic consult, which is increasingly being adopted 
to seek specialist input [34, 35]. Additional information 
on how the Informatics Consult differs from traditional 
approaches to evidence generation and use is summa-
rised in Additional file 1-1.
Concordance across sources of evidence identified 
from the Consult
A primary motivation for requesting an Informatics Con-
sult is to understand how a particular treatment influ-
ences an outcome to help guide decision making. We 
show a degree of concordance across four sources of evi-
dence. RCTs demonstrate the effectiveness of oral anti-
coagulation in stroke prevention in patients with atrial 
fibrillation: but as we demonstrate reported and currently 
recruiting RCTs exclude patients with cirrhosis (i.e., 
patients having ‘contraindications’ for anticoagulants). 
This suggests that the prospect of ever mounting, or suc-
cessfully recruiting to, an RCT in patients with AF and 
cirrhosis is low. Meta-analysis of observational studies 
and target trial emulation suggest evidence on the poten-
tial benefits of warfarin for stroke reduction, suggest-
ing the significant impact on strokes and deaths averted 
if these patients are treated with anticoagulant therapy. 
Although we did not find any relevant GWAS summary 
data, evidence suggests that lower levels of vitamin K1 
(target of warfarin) are associated with lower stroke risk 
which is corroborated by another study [36].
Returning results on prevalence, prognosis and treatment 
variation
Interestingly, the clinicians involved in this study rec-
ommended that information beyond efficacy and safety 
should be included as options for the clinician to request 
in the Informatics Consult. By providing information 
on the prevalence of cirrhosis and atrial fibrillation, we 
demonstrate that this pair of conditions is not highly 
prevalent (although not considered rare). Knowing that 
the health system has data on diagnosis, treatment and 
outcomes in an estimated 35,000 individuals (scaled up 
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to the population of England) with both conditions, high-
lights the importance of several areas. First, the impor-
tance of accessing and learning from nationwide data at 
scale; any one clinician may have clinical experience of 
only a handful of such cases, and it is not feasible or scal-
able to create registries. Second, the clinician likely has 
never had access before to population-based, contem-
porary prognostic information on such patients (1-year 
mortality: 15%), nor the knowledge that in practice 43% 
of patients were started on warfarin. We anticipate that 
providing clinicians and patients with this information 
may stimulate further questions on generating new Con-
sults on a wider range of prognostic outcomes, and pre-
dictors of prognosis.
Need and demand for informatics consult
Nearly all clinicians are faced with treatment decisions 
where limited evidence exists where insights might be 
gained from analysis of large-scale data on ‘patients like 
me’. Previous studies have employed EHR data for diag-
nostic consultations [37], and others have created clinical 
informatics consult services based on the medical litera-
ture [38]. But currently, few if any clinicians can request 
such insights. A clinician from the survey mentioned 
that evidence from the Informatics Consult is important 
to help their decision in practicing defensive medicine 
given that the majority of clinical practice recommenda-
tions in professional society guidelines are not supported 
by RCT evidence. There is limited information on the 
system-wide frequency of treatment ’clashes’ where indi-
cation and contraindications coexist in the same patient. 
This is especially relevant for patients with multimor-
bidity where evidence from RCTs are limited [6], which 
may result in individuals being subjected to low-quality 
recommendations. For example, certain targeted cancer 
therapy such as angiogenesis inhibitors may cause an 
increase the prevalence of hypertension during treat-
ment, which highlights the importance of considering the 
impact of cancer therapy on adverse side effects and car-
diotoxicity [39]. Our preliminary analyses demonstrate 
that 26 in 10,000 women have breast cancer and hyper-
tension; these individuals might benefit from the Infor-
matics Consult.
Developing the informatics consult as a service
The majority of clinicians in our survey thought that 
they should have access to the Informatics Consult as 
a service as their healthcare systems seek to learn from 
existing data [40]. We have demonstrated the feasibility 
with this one example. Scaling to other clinical exam-
ples, and a service, requires five inter-related challenges 
to be addressed in clinical standards setting, imple-
mentation and evaluation, access to data, informatics, 
and knowledge management. First, bodies that define 
standards of care—including clinical practice guideline 
developers and regulatory and technology assessment 
bodies—are already considering real-world evidence 
generated in conventional timescales [7, 41]. In the con-
text of a more rapid generation of evidence, the Infor-
matics Consult raises new questions about replication, 
open peer review and quality assurance pipelines. Sec-
ond, development, implementation and evaluation of 
the impact of the Informatics Consult on clinical deci-
sion making in practice are required. Feedback from 
our survey suggests that multidisciplinary team (MDT) 
meetings, which concentrate on ‘difficult’ clinical cases 
may present an opportunity [42]. Third, an Informatics 
Consult service requires approved, immediate access to 
large scale, clinically detailed updated data, most likely 
in a trusted research environment. The coronavirus pan-
demic offers a new precedent for such information gov-
ernance approvals, which can not foresee the nature of 
the next clinician’s question. Fourth, biomedical knowl-
edge (in EHRs, trial protocols, clinical guidelines) needs 
to become more computable and interoperable. Design 
and analysis methods need to be improved, standardized 
and widely distributed. For example, the Observational 
Health Data Science and Informatics community offers 
open-source software implementing many routine analy-
ses methods [43]. Fifth, there needs to be an open pro-
cess of making the knowledge available in an Informatics 
Consult library. As the library builds, Clinicians might 
make a request for which a previous consult already pro-
vides an answer. The Library might also serve as a plat-
form for connecting ‘patients like me’, registering the 
frequency of therapeutic dilemmas and potential treat-
ment uncertainties, identifying the need for new RCTs, 
and informing their design and facilitate targeted recruit-
ment into trials.
Strengths of the study
To the best of our knowledge, this is the first demon-
stration of Informatics Consult for a treatment decision, 
triangulation of evidence from meta-analyses of obser-
vational studies, target trial emulation using EHR data 
and MR. The breadth, depth and longevity (long follow-
up period) of the EHR data, which links primary care, 
secondary care and the death registry is an advantage. 
Another significant strength is engagement with an inde-
pendent sample of clinicians from multiple specialties to 
gauge the feasibility and acceptability of the Informatics 
Consult.
Limitations of the study
Our study has important limitations. First, although we 
have prototyped EHR request and report forms based on 
Page 12 of 14Lai et al. BMC Med Inform Decis Mak          (2021) 21:281 
feedback from clinicians, these have not yet been imple-
mented in live clinical systems. Second, as initial proof 
of concept, we have not assessed bleeding outcomes and 
newer non-vitamin K oral anticoagulants due to cur-
rent data access limitations. Third, it remains difficult to 
assess whether there unmeasured confounding despite 
employing causal inference methods. It is also possi-
ble that some prescription data is missing, which means 
that patients are incorrectly assigned to the control 
arms. Future analyses on a more recent and larger data-
set involving both CPRD Gold and Aurum [44] would be 
beneficial. Fourth, a limitation of the MR analyses is that 
access to summarised GWAS data for stroke outcomes in 
patients with cirrhosis is limited. The advantages of using 
publicly available GWAS summarised data are speed and 
transparency, both of which are essential to the Informat-
ics Consult. Although individual-level data would allow 
more flexibility to conduct analyses in specific patient 
subgroups and to select which variables to generate the 
summarised data for, such analyses could not be returned 
within a clinical timescale that is not scalable and can-
not be fully automated. Fifth, although we have identified 
potential ways to automate the analytic process, these 
have not been implemented here.
Conclusion
We proposed an Informatics Consult framework to sum-
marize evidence from four sources and have developed a 
report prototype for answering a treatment question to 
enable new ways of data-informed decision making. The 
Informatics Consult may stimulate a conversation among 
public, professionals and policymakers about more rap-
idly realising the benefits of health system learning from 
‘patients like me’.
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